Why the MGC Pharma (ASX:MXC) share price is zooming 13% higher today

The MGC Pharma (ASX: MXC) share price is up 13% in morning trade. We look at the latest from the ASX cannabis share.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is off to the races today, up 13% at the time of writing.

The bio-pharma company produces and develops cannabis-derived medicines.

Let's take a look at the ASX cannabis share's latest product orders and revenue stream.

cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

What did MGC Pharma report today?

The MGC Pharma share price is rocketing higher after the company reported it had completed the delivery of its first bulk order of ArtemiC Rescue in March to Swiss PharmaCan AG. The bulk order of its medicinal food supplement delivered approximately $425,000 in wholesale production revenue.

Swiss PharmaCan's purchase helped drive MGC Pharma to record quarterly sales revenue from its "proprietary phytomedicine product line". The ASX cannabis share reported it had generated roughly $880,000 of revenue during the March 2021 quarter.

The company also said March brought in its best single month's sales revenue so far from its pharmaceutical-grade phytomedicine products, driven by sales of its MP product line in Australia.

Words from the management

Commenting on the results, MGC Pharma global chief sales officer Nicole Godresse said:

In recent months we have seen rapid sales growth of our medical cannabis products as a direct result of our strategy to broaden our core prescriber base, diversify and expand our revenue streams and build additional strategic alliances. It is pleasing to see these strategies starting to translate into positive commercial outcomes and we expect this strong growth momentum to continue in 2021 and beyond.

MGC Pharma managing director Roby Zomer added:

We are very pleased to complete our first batch purchase order for ArtemiC Rescue under our Swiss PharmaCan agreement. This, combined with sales growth of other pharma grade cannabinoid products in key markets, has helped to deliver the strongest month and quarter of revenue growth for the company to date.

MGC Pharma's detailed March quarterly activity report is expected within the next few weeks.

MGC Pharma share price snapshot

Over the past 12 months, the MGC Pharma share price has gained 130%, handily outpacing the 35% gains posted by the All Ordinaries Index (ASX: XAO) over that same period.

With today's intraday gains factored in, the MGC Pharma share price is up 245% year-to-date.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »